Metraipolis › archive › dc_43f2e8967565
Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a… — Europe PMC PMID:41426315
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41426315
- DOI
- 10.3389/fonc.2025.1637973
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T21:40:39.712Z
- SHA-256 of the archived text
1c0c233f8e7773c3ccd94b5ef5c8a0b12f42458a26fa0fba5534f881af143e6c- Stable URL of this page
https://metraipolis.com/documento/dc_43f2e8967565
How to cite
Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a… — Europe PMC PMID:41426315 — Europe PMC (en), https://europepmc.org/article/MED/41426315 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_43f2e8967565 (Metraipolis archive dc_43f2e8967565, sha256 1c0c233f8e7773c3ccd94b5ef5c8a0b12f42458a26fa0fba5534f881af143e6c)
BibTeX
@misc{dc43f2e8967565,
title = {Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a… — Europe PMC PMID:41426315},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41426315},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_43f2e8967565; sha256 1c0c233f8e7773c3ccd94b5ef5c8a0b12f42458a26fa0fba5534f881af143e6c},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41426315. Agents can read the archived copy with the MCP tool read_document.